|
Heute steigt die Aktie nicht nur im außerbörslichen Handel, wie in den letzten Tagen üblich, sondern auch im regulären Handel Momentan bei 0,14 US$ (+27,3%). Vielleicht ist diese aktuelle Meldung der Grund: Viragen Featured In `Science Magazine` PLANTATION, Fla., May 6, 2003 /PRNewswire-FirstCall via COMTEX/ -- Viragen, Inc. (Amex: VRA) today announced its Avian Transgenic Production Technology Project is featured in an article in the May 2, 2003 edition of "Science." The article by Joe Alper entitled: "Hatching the Golden Egg: A New Way to Make Drugs" discusses Viragen`s project with Scotland`s Roslin Institute to create flocks of transgenic chickens as a cost-effective and efficient manufacturing platform for the large-scale production of protein-based drugs. The article can be accessed at Viragen`s website at http://www.viragen.com. About Viragen, Inc. Viragen is a biotechnology company specializing in the research, development and commercialization of natural and recombinant protein-based drugs designed to treat a broad range of viral and malignant diseases. These protein-based drugs include human natural alpha interferon, monoclonal antibodies, peptide drugs and therapeutic vaccines. Viragen`s strategy also includes the development of Avian Transgenic Technology for the large-scale, cost-effective manufacturing of its portfolio of protein-based drugs, as well as offering Contract Manufacturing for the entire biopharmaceutical industry. Viragen is publicly traded on the American Stock Exchange (VRA). Viragen`s majority owned subsidiary, Viragen International, Inc., is publicly traded on the Over-The-Counter Bulletin Board (VGNI). Viragen`s key partners and licensors include: Roslin Institute, Memorial Sloan-Kettering Cancer Center, National Institutes of Health, Cancer Research UK, University of Nottingham (U.K.), University of Miami, America`s Blood Centers and the German Red Cross. For more information, please visit our Web site at: www.Viragen.com Viragen, Inc. Corporate Contacts: Douglas Calder, Director of Communications (Media & Investor Contact) Phone: (954) 233-8746; Fax: (954) 233-1414 E-mail: dcalder@viragen.com Gruß Fraktal |
|
| aus der Diskussion: | Viragen - aktueller Artikel im Science Magazin |
| Autor (Datum des Eintrages): | Frakt@l (06.05.03 22:02:34) |
| Beitrag: | 1 von 128 (ID:9374287) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |